Sientra (SIEN) Misses Q1 EPS by 15c, Beats on Revenues

Sientra (NASDAQ: SIEN) reported Q1 EPS of ($0.99), $0.15 worse than the analyst estimate of ($0.84). Revenue for the quarter came in at $14.68 million versus the consensus estimate of $11.87 million.

Jeffrey M. Nugent, Chairman and Chief Executive Officer of Sientra, said, “We achieved the highest net revenue in the Company’s history which further reinforced our diversification strategy and will serve as the foundation for another transformational year of growth and expansion. With the recent FDA approval of our PMA supplement, we anticipate that the commercialization of our OPUS-branded silicone breast implants with strong 10-year clinical data and our new Sientra Platinum20™ warranty program will drive market share gains as we strengthen our commitment to the safety, reliability and quality of our products. We also expect that the enhanced protocol for miraDry fresh combined with our recently launched digital marketing campaign will drive meaningful contributions under an expanded commercial organization. Looking ahead, we are excited to continue leveraging our exceptional products, people, and relationships to take share across segments and drive value as a diversified global aesthetics company.”

For earnings history and earnings-related data on Sientra (SIEN) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Pro Diversity Network (IPDN) Reports Q2 Loss of $0.15
• Hydrofarm Holdings Group, Inc. (HYFM) Misses Q2 EPS by 134c